Can chemoprevention reduce the risk of prostate cancer?
Diamandis
Eleftherios P
EP
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada. ediamandis@mtsinai.on.ca
D016588:Anticarcinogenic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001378:Azasteroids / Q000009:adverse effects / Q000627:therapeutic use*; D000068538:Dutasteride; D018120:Finasteride / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000517:prevention & control*; D012306:Risk
D016588:Anticarcinogenic Agents; D001378:Azasteroids; D018120:Finasteride; D000068538:Dutasteride